Literature DB >> 8684836

Influence of host and parasite genotypes on immunological control of Theileria parasites.

W I Morrison1.   

Abstract

Infections with Theileria parva in the African buffalo are invariably asymptomatic, whereas infections in cattle usually result in clinical disease, the severity of which varies in different populations of cattle. The parasite exhibits antigenic heterogeneity, which in cattle manifests as differences between parasite strains in their cross-protective properties. A series of studies on T cell responses to T. parva in cattle have demonstrated that class I MHC-restricted cytotoxic T lymphocytes (CTL), specific for parasitized lymphoblasts, are important mediators of immunity. Cytotoxic T cell responses frequently display parasite strain-restricted specificities which appear to correlate with the capacity of strains to cross-protect. The strain specificity of CTL responses varies in animals immunized with the same parasite strain and is influenced by both host and parasite genotype. Recent studies have provided evidence that there is competition between epitopes for induction of CTL responses, which can result in a bias to strain-specific epitopes. These properties of the CTL response have important implications for vaccination. Thus, in designing a vaccine, it may be possible, by selecting parasite proteins containing appropriate CTL epitopes, to generate CTL responses that protect against a wide range of parasite strains. Although there are no comparable data on CTL responses in the buffalo, it is considered that the features of the immune response described for cattle would be advantageous for survival of parasite populations in the buffalo. Specifically, a bias in the immune responses to strain-specific determinants should favor establishment of infection in buffalo already carrying the parasite and allow fluctuation in the levels of different parasite strains during the course of persistent infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8684836

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  6 in total

Review 1.  Theileria parva and the bovine CTL response: down but not out?

Authors:  D J McKeever
Journal:  Parasite Immunol       Date:  2006-07       Impact factor: 2.280

2.  Influence of host immunity on parasite diversity in Theileria parva.

Authors:  Frank Katzer; Daniel Ngugi; Christian Schnier; Alan R Walker; Declan J McKeever
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

3.  MHC class I bound to an immunodominant Theileria parva epitope demonstrates unconventional presentation to T cell receptors.

Authors:  Isabel K Macdonald; Maria Harkiolaki; Lawrence Hunt; Timothy Connelley; A Victoria Carroll; Niall D MacHugh; Simon P Graham; E Yvonne Jones; W Ivan Morrison; Darren R Flower; Shirley A Ellis
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

4.  Theileria annulata-transformed cell lines are efficient antigen-presenting cells for in vitro analysis of CD8 T cell responses to bovine herpesvirus-1.

Authors:  Jane Hart; Niall D MacHugh; W Ivan Morrison
Journal:  Vet Res       Date:  2011-12-19       Impact factor: 3.683

Review 5.  Immune Response to Tick-Borne Hemoparasites: Host Adaptive Immune Response Mechanisms as Potential Targets for Therapies and Vaccines.

Authors:  Alessandra Torina; Valeria Blanda; Sara Villari; Antonio Piazza; Francesco La Russa; Francesca Grippi; Marco Pio La Manna; Diana Di Liberto; José de la Fuente; Guido Sireci
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

6.  CD8+ T-cell responses to Theileria parva are preferentially directed to a single dominant antigen: Implications for parasite strain-specific immunity.

Authors:  Niall D MacHugh; Timothy Connelley; Simon P Graham; Roger Pelle; Principia Formisano; Evans L Taracha; Shirley A Ellis; Declan J McKeever; Alison Burrells; W Ivan Morrison
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.